NR1H4 and metabolic dysfunction-associated steatotic liver disease: Considering the early report that Alisol B’s analogue protected against NAFLD via FXR activation [25], FXR luciferase reporter assay was carried out, while Alisol B showed no direct agonistic activity on FXR (Figure 6H).